A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB

BACKGROUND: Treatment for TB is lengthy and toxic, and new regimens are needed. METHODS: Participants with pulmonary drug-susceptible TB (DS-TB) were randomised to receive: 200 mg pretomanid (Pa, PMD) daily, 400 mg moxifloxacin (M) and 1500 mg pyrazinamide (Z) for 6 months (6Pa(200)MZ) or 4 months (...

Descripción completa

Detalles Bibliográficos
Autores principales: Tweed, C. D., Wills, G. H., Crook, A. M., Amukoye, E., Balanag, V., Ban, A. Y.L., Bateson, A. L.C., Betteridge, M. C., Brumskine, W., Caoili, J., Chaisson, R. E., Cevik, M., Conradie, F., Dawson, R., del Parigi, A., Diacon, A., Everitt, D. E., Fabiane, S.M., Hunt, R., Ismail, A. I., Lalloo, U., Lombard, L., Louw, C., Malahleha, M., McHugh, T. D., Mendel, C. M., Mhimbira, F., Moodliar, R. N., Nduba, V., Nunn, A. J., Sabi, I., Sebe, M. A., Selepe, R. A. P., Staples, S., Swindells, S., van Niekerk, C. H., Variava, E., Spigelman, M., Gillespie, S. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Union Against Tuberculosis and Lung Disease 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009598/
https://www.ncbi.nlm.nih.gov/pubmed/33762075
http://dx.doi.org/10.5588/ijtld.20.0513

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8009598/
https://www.ncbi.nlm.nih.gov/pubmed/33762075
http://dx.doi.org/10.5588/ijtld.20.0513

Ejemplares similares